Soleno Therapeutics, Inc. (SLNO) Debt by Year
Soleno Therapeutics, Inc. carried $49.9M in long-term debt against $70.1M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 0.1% from the prior fiscal year. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Soleno Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SLNO Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $49.9M+0.1% | $49.8M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $70.1M-20.3% | $87.9M-48.2% | $169.7M+1062.0% | $14.6M-31.5% | $21.3M-56.7% | $49.2M+137.4% | $20.7M-10.2% | $23.1M+35.1% | $17.1M+527.3% | $2.7M-50.4% | $5.5M-30.9% | $8.0M+527.1% | $1.3M |
SLNO Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $49.9M+0.1% | $49.9M+0.1% | $49.9M | $49.8M | $49.8M | $49.8M | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $133.0M+63.6% | $70.1M-20.3% | $246.7M+409.5% | $76.5M+34.1% | $81.3M+89.8% | $87.9M-48.2% | $48.4M-7.7% | $57.0M+194.4% | $42.8M+444.2% | $169.7M+1062.0% | $52.4M+165.5% | $19.4M-19.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Soleno Therapeutics, Inc. financials
Frequently Asked Questions
What was Soleno Therapeutics, Inc.'s long-term debt in fiscal year 2025?
Soleno Therapeutics, Inc. carried $49.9M in long-term debt against $70.1M in cash and equivalents at the end of fiscal year 2025.
How fast is Soleno Therapeutics, Inc.'s long-term debt growing?
Soleno Therapeutics, Inc. (SLNO) long-term debt rose by 0.1% year over year, from $49.8M to $49.9M in fiscal year 2025.
What was Soleno Therapeutics, Inc.'s long-term debt in the most recent quarter?
Soleno Therapeutics, Inc. (SLNO) reported $49.9M in long-term debt in Q1 2026. This represents an increase of 0.1% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Soleno Therapeutics, Inc. (SLNO) reported on that line in every period on record.